NCT04864054View on ClinicalTrials.gov

T-Cell Therapy (ECT204) in Adults With Advanced HCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Hepatocellular CarcinomaLiver Cancer, AdultLiver NeoplasmMetastatic Liver Cancer
Interventions
BIOLOGICAL

ECT204 T cells

ECT204 is an autologous T-cell therapy whereby a subject's own T cells are transduced with a lentiviral vector expressing the ECT204 transgene.

DRUG

Regorafenib (STIVARGA®, BAY73-4506)

Regorafenib pretreatment before an ECT204 infusion.

Trial Locations (5)

106

RECRUITING

National Taiwan University Cancer Center, Taipei

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

66205

COMPLETED

Kansas University Medical Center, Principal Investigator:, Westwood

91010

RECRUITING

City of Hope, Duarte

98109

RECRUITING

Fred Hutchinson Cancer Center, University of Washington, Seattle

Sponsors
All Listed Sponsors
lead

Eureka Therapeutics Inc.

INDUSTRY

NCT04864054 - T-Cell Therapy (ECT204) in Adults With Advanced HCC | Biotech Hunter | Biotech Hunter